• Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 53.85%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.25
+0 (0.00%)

This chart shows the closing price for ELUT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Elutia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELUT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELUT

Analyst Price Target is $5.00
▲ +53.85% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Elutia in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 53.85% upside from the last price of $3.25.

This chart shows the closing price for ELUT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Elutia. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$6.00 ➝ $5.00Low
11/14/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$8.00 ➝ $6.00Low
9/28/2023Lake Street CapitalInitiated CoverageBuyLow
9/26/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$8.00Low
9/19/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$8.00Low
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$8.00Low
8/15/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$8.00Low
5/12/2023Cantor FitzgeraldLower Target$12.00 ➝ $10.00Low
11/16/2022Truist FinancialBoost TargetBuy$8.00 ➝ $10.00Low
11/15/2022Piper SandlerBoost TargetOverweight$9.00 ➝ $10.50Low
5/24/2022Cantor FitzgeraldReiterated RatingOverweightHigh
3/4/2022CowenLower TargetOutperform$15.00 ➝ $13.00High
11/11/2021Cantor FitzgeraldReiterated RatingOverweightLow
11/9/2021Piper SandlerLower TargetOverweight$14.00 ➝ $11.00High
11/2/2020Truist FinancialInitiated CoverageBuy ➝ Buy$20.00High
11/2/2020Piper SandlerInitiated CoverageOverweight$20.00High
11/2/2020CowenInitiated CoverageOutperform$20.00High
11/2/2020Cantor FitzgeraldInitiated CoverageOverweight$20.00High
(Data available from 5/27/2019 forward)

News Sentiment Rating

-0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2023
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/27/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/26/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Elutia logo
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Read More

Today's Range

Now: $3.25
Low: $3.01
High: $3.39

50 Day Range

MA: $3.08
Low: $2.77
High: $3.42

52 Week Range

Now: $3.25
Low: $1.10
High: $4.19

Volume

4,900 shs

Average Volume

24,079 shs

Market Capitalization

$78.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Elutia?

The following Wall Street research analysts have issued research reports on Elutia in the last year: Cantor Fitzgerald, and Lake Street Capital.
View the latest analyst ratings for ELUT.

What is the current price target for Elutia?

1 Wall Street analysts have set twelve-month price targets for Elutia in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 53.8%. Cantor Fitzgerald has the highest price target set, predicting ELUT will reach $5.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $5.00 for Elutia in the next year.
View the latest price targets for ELUT.

What is the current consensus analyst rating for Elutia?

Elutia currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ELUT will outperform the market and that investors should add to their positions of Elutia.
View the latest ratings for ELUT.

What other companies compete with Elutia?

How do I contact Elutia's investor relations team?

Elutia's physical mailing address is 12510 Prosperity Drive, Suite 370, Silver Spring, MD 20904, United States. The company's listed phone number is 240-247-1170 and its investor relations email address is [email protected]. The official website for Elutia is www.elutia.com. Learn More about contacing Elutia investor relations.